Issue Information – Table of Contents
Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis
Bloodstream infections caused by Klebsiella pneumoniae in onco‐hematological patients
Glucosylsphingosine is a key biomarker of Gaucher disease
The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
Patterns of opioid use in sickle cell disease
Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant
Low incidence of pneumocystis pneumonia utilizing PCR‐based diagnosis in patients with B‐cell lymphoma receiving rituximab‐containing combination chemotherapy
A candidate transacting modulator of fetal hemoglobin gene expression in the Arab—Indian haplotype of sickle cell anemia
Outcomes of patients with renal monoclonal immunoglobulin deposition disease
N‐terminal fragment of the type‐B natriuretic peptide (NT‐proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma
2017 Clinical trials update in new treatments of β‐thalassemia
Systemic mastocytosis in adults
Transplant‐associated thrombotic microangiopathy
Extracavitary primary effusion lymphoma associated with hemophagocytic lymphohistiocytosis
Blood smear, a key diagnostic tool in hematology
Intense focal pituitary FDG uptake due to intravascular large B‐cell lymphoma in pyrexia of unknown origin
Testing for dabigatran and rivaroxaban by clinical laboratories
Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia
Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma
Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia
Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia